The Alter Pharma Group is proud to announce having acquired EcoPharmaSupply (EPS). EPS is a Belgian pharmaceutical services and products company, distributor and partner of choice for several pharmaceutical brands on the Benelux market including prescription drugs, medical devices, OTC pharmaceuticals and consumer health products. The investment will allow Alter Pharma to enhance its services and product offering further leveraging its regulatory compliance and market know-how while leaning on its extensive procurement and logistics network. Through this acquisition, which was closed on 4 April 2022, Alter Pharma further expands its toolkit for supporting both retail and hospital pharmacists in their quest to deliver high quality service and products to their patients. Please...
News
Milla Pharmaceuticals Announces Approval of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers.
Milla Pharmaceuticals, a subsidiary of the Alter Pharma Group, announced that it has received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for its generic version of Magnesium Sulfate in Water for Injection, 2 g/50 mL (40 mg/mL), 4 g/100 mL (40 mg/mL), and 4 g/50 mL (80 mg/mL), in Non-PVC, Single-Patient Use Containers (Magnesium Sulfate Injection). Magnesium Sulfate Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously, it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous...
Milla Pharmaceuticals Announces Approval and Launch of a Generic Version of Sodium Acetate Injection 2MEQ/mL by Pfizer Inc.
– Company granted 180-days of exclusivity under FDA Competitive Generic Therapy approval pathway – Milla Pharmaceuticals, a subsidiary of the Alter Pharma Group, announced that it has received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for its generic version of Sodium Acetate Injection 2MEQ/mL. Milla Pharmaceuticals was previously granted a Competitive Generic Therapy (CGT) designation for its generic drug by the FDA, which is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also...